Side Effects of Allergy Drops: From Mild Tingling to Rare Severe Reactions

Side effects of allergy drops vary by individual and by allergen. Dust mite drops tend to produce higher throat irritation rates — Odactra pivotal trials showed throat irritation in 67% of patients — while grass formulations show oral pruritus as the dominant effect (26.7% in Grastek trials). Multi-allergen drops may produce different patterns depending on the specific combination. Individual immune reactivity also varies: some patients experience prominent oral tingling with every dose throughout build-up, while others report very little discomfort from the first dose. Age matters too: children may describe the sensation differently and may initially resist dosing if oral effects are noticeable. The common thread across all SLIT patients is that oral-local effects — whatever their character — diminish substantially during the first 4-8 weeks of consistent dosing as local mucosal tolerance establishes itself.

Mild throat sensations — irritation, scratchiness, or a feeling of tightness — are common with SLIT drops, affecting up to 67% of patients in dust mite studies (Odactra FDA label). This is distinct from throat swelling (angioedema), which is uncommon and constitutes a moderate-to-severe adverse event requiring allergist contact. True throat swelling that causes voice changes, difficulty swallowing, or breathing difficulty is a more serious symptom that should be treated as a systemic reaction: stop drops, use epinephrine if prescribed and symptoms are severe, and seek medical care. If you are unsure whether your throat discomfort is the normal oral-local irritation or something more significant, the key distinguishing factor is whether it affects breathing or swallowing — if either is compromised, treat as urgent.

Allergy drops (sublingual immunotherapy) do not cause weight gain. This side effect is associated with corticosteroid medications — not with allergen immunotherapy. SLIT works by delivering allergen extracts to the oral mucosa to retrain immune tolerance; it does not involve steroids, appetite-stimulating hormones, or any mechanism that would produce weight changes. The confusion likely stems from the fact that some patients receive steroid injections (such as triamcinolone) for allergy symptom relief — these are completely different medications. If you are experiencing unexplained weight changes while using any allergy treatment, discuss this with your doctor to identify the actual cause, as it is unlikely to be related to your sublingual immunotherapy.

The key distinguishing feature between a normal oral-local reaction and an abnormal systemic reaction is location: normal reactions stay in the mouth, throat, and ears. Itching under the tongue, throat scratchiness, brief ear pruritus, and mild lip tingling — all limited to the oral cavity — are expected effects that indicate the immune system is responding to allergen exposure. These typically resolve within 15-30 minutes. Abnormal reactions extend beyond the oral cavity: hives on the body, generalized itching not localized to the mouth, wheezing, throat swelling that impairs swallowing or breathing, dizziness, or GI cramping severe enough to limit daily activity. Oral-local reactions that are genuinely uncomfortable but limited to the mouth are not dangerous. Any symptom that spreads beyond the oral cavity warrants a call to your allergist before the next dose.

Eosinophilic esophagitis (EoE) is an inflammatory condition of the esophagus characterized by an abnormal accumulation of eosinophil immune cells in the esophageal lining. Its primary symptom is dysphagia — difficulty swallowing — and in severe cases, food impaction (food getting stuck during swallowing). EoE has been reported in approximately 0.07% of patients in Odactra (dust mite SLIT tablet) clinical trials — roughly 2 of 2,737 patients. This incidence, while rare, appears specific to the sublingual route and may relate to repeated allergen exposure in the GI mucosa. If you develop progressive difficulty swallowing, food impaction, or persistent chest discomfort during SLIT treatment, stop drops and contact your allergist and gastroenterologist. EoE typically requires endoscopic evaluation and SLIT discontinuation. The condition is rare but important to recognize.

Anaphylaxis from allergy drops is extraordinarily rare — one of the least common serious adverse events in allergy medicine. In pooled FDA data across SLIT tablet trials, 3 of 8,200 patients (approximately 0.02-0.04%) experienced treatment-related anaphylaxis, none of which were life-threatening or required hospitalization (Nolte 2024). Extrapolating to the global SLIT experience: approximately 11-30 published anaphylaxis cases exist against an estimated 1 billion administered SLIT doses (Calderon 2012). No SLIT fatality has ever been confirmed. For context, anaphylaxis occurs in approximately 1 per 160,000 allergy shot visits — itself a low rate, but measurably higher than SLIT. The FDA's Boxed Warning on approved SLIT products is a regulatory precaution based on theoretical risk, not a reflection of the observed adverse event rate in clinical use.